ArticleMedicine2026
Serum magnesium and depressive symptoms among U.S. adults: A cross-sectional study of NHANES august 2021-august 2023.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Magnesium participates in neurotransmission, stress regulation, and inflammatory signaling, but epidemiological evidence linking circulating magnesium to depression is inconsistent. Serum magnesium remains clinically accessible and objectively measured, yet recent nationally representative evidence is limited. We analyzed 4061 adults aged ≥20 years from National Health and Nutrition Examination Survey August 2021 to August 2023. Moderate-to-severe depressive symptoms were defined as Patient Health Questionnaire-9 (PHQ-9) score ≥10. Serum magnesium was modeled as survey-weighted quartiles and per 1-standard-deviation increase. Analyses used the National Health and Nutrition Examination Survey phlebotomy weight (WTPH2YR), strata, and primary sampling units. Survey-weighted logistic regression, 3-knot restricted cubic splines, sex-stratified analyses, formal interaction testing, and sensitivity analyses were performed. Serum magnesium was not independently associated with moderate-to-severe depressive symptoms in the overall U.S. adult population. A male-specific inverse signal was observed but was not supported by a statistically significant sex interaction and should be considered exploratory. Serum magnesium did not emerge as a sensitive population-level indicator of depressive symptom status. The weighted prevalence of PHQ-9 ≥10 was 11.7%. In fully adjusted models, serum magnesium was not associated with moderate-to-severe depressive symptoms. Compared with Q1, odds ratios (ORs) for Q2 to Q4 were 0.82 (95% confidence interval [CI], 0.59-1.14), 0.90 (0.67-1.20), and 0.92 (0.59-1.44), respectively. The OR per 1-standard deviation increase was 0.92 (0.83-1.03; P = .134). Overall restricted cubic spline tests were nonsignificant (P-overall = .273; P-nonlinear = .679). An inverse association was observed in men (OR, 0.78; 95% CI, 0.64-0.96; P = .021) but not women (OR, 1.04; 95% CI, 0.91-1.19; P = .544); however, the magnesium-by-sex interaction was not significant (P-interaction = .113). Findings were unchanged using PHQ-9 ≥5, excluding estimated glomerular filtration rate <30 mL/min/1.73 m2, adjusting for dietary-magnesium, or additionally adjusting for serum calcium and 25-hydroxyvitamin D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.